In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)


Antimicrobial resistance could be one of the main causes of excess mortality in future decades. Fighting antimicrobial resistance is an imperative objective for the entire scientific community and in the interest of society worldwide. In this battle, it is crucial to reduce inappropriate antibiotic prescription/consumption by improving diagnostic tools and optimizing their use. Currently, antibiotic therapy is usually started on an empiric basis since usual microbiological tests can provide results in a frame of four hours to five days in most cases. This leads to frequent overuse and misuse of antibiotics, both being a leading cause of antimicrobial resistance and extra costs for health care systems.
The identification of feasible strategies to improve antibiotic stewardship is one of the goals of ECRAID (European Clinical Research Alliance for Infectious Diseases). ECRAID is a European clinical research network (funded through H2020 call SC1- HCO-08-2018 - No. 965313, ECRAID-Base). ECRAID aims at increasing efficiency for testing and developing new diagnostic, preventive, and/or therapeutic strategies and therapies, and improving responsiveness to new public health threats created by emerging infectious diseases.
The present Research Seminar will complement the existing ECRAID-Base activities and will benefit the ECRAID consortium members, ERS, ESCMID and Value-dx members involved in the field of AMR.

Welcome and introduction

Health economic models for diagnostics

Landscaping of diagnostic tests for RTI

How IVD really improve clinical outcomes in the management of LRTI

Adaptive clinical trials and new approaches in the field of research of respiratory infections

The new IVD Regulation (IVDR) as current framework for IVD microbiological diagnostic tests

Round table discussion